Radioactive antibody targets Hard-to-Treat cancers in early trial
NCT ID NCT07189871
First seen Sep 30, 2025 · Last updated Jun 19, 2026 · Updated 26 times
Summary
This early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will enroll about 61 participants and aims to find the safest dose and see if the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BAMF Health
RECRUITINGGrand Rapids, Michigan, 49503, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dothan Hematology & Oncology
RECRUITINGDothan, Alabama, 36303, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nebraska Cancer Specialists
RECRUITINGOmaha, Nebraska, 68130, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
XCancer
RECRUITINGOmaha, Nebraska, 68130, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.